Item 8.01 Other Events.
Between
On
The Company believes that its existing cash, cash equivalents and investments, together with the anticipated proceeds from the registered direct offering will enable it to fund its current business plan, including the Company's planned clinical trial of ALRN-6924 in patients with non-small cell lung cancer, into the second half of 2023.
Forward-Looking Statements
Statements in this report about Company's future expectations, plans and
prospects, as well as any other statements regarding matters that are not
historical facts, may constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements about the Company's belief that its
existing cash, cash equivalents and investments will enable it to fund its
current business plan including related operating expenses and capital
expenditures into the second half of 2023. The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking statements as a
result of various important factors, including whether the conditions to the
closing of the registered direct offering will be satisfied; whether the
Company's cash resources will be sufficient to fund its continuing operations
for the periods and/or trials anticipated; whether results obtained in clinical
trials will be indicative of results obtained in future clinical trials; whether
third party data would be indicative of the data that would be obtained in a
randomized, head-to-head clinical trial; whether the Company's product
candidates will advance through the clinical trial process on a timely basis, or
at all; whether the results of such trials will be accepted by and warrant
submission for approval from the
--------------------------------------------------------------------------------
© Edgar Online, source